If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT01597895","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Nonrandomized Trial","arm_groups":[{"arm_group_label":"Maraviroc","arm_group_description":"","arm_type":"Active Comparator"},{"arm_group_label":"Maraviroc + Boceprevir","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"Maraviroc + Telaprevir","arm_group_description":"","arm_type":"Experimental"}],"assignment":"Cross-over","brief_summary":"The purpose of this study is to determine the effect that telaprevir and boceprevir has on the pharmacokinetics of maraviroc.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects","conditions":[{"DisplayValue":"Other","DisplayValue_OneLinkTx":"","InternalValue":"CON_OTHER","LookupValue":"Healthy","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:54:06","criteria":"Inclusion Criteria: - Healthy male and/or female subjects. - Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. - Total body weight >50 kg (110 lbs). Exclusion Criteria: - Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. - Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day. - Positive result for HIV-1, HIV-2, Hepatitis B serology (HbsAg, HbcAb) or anti hepatitis C virus serology (as determined by a multi antigen EIA).","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"14","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"84b0b937-9ac5-53e4-b622-9cca6ad7d454","internal":{"content":null,"contentDigest":"88469493add4ebd787035612c26754f5","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Healthy male and/or female subjects. - Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. - Total body weight >50 kg (110 lbs). Exclusion Criteria: - Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. - Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day. - Positive result for HIV-1, HIV-2, Hepatitis B serology (HbsAg, HbcAb) or anti hepatitis C virus serology (as determined by a multi antigen EIA).","interventions":[{"arm_group_label":"Maraviroc","intervention_description":"Maraviroc 150 mg BID x 5 days with food","intervention_name":"Maraviroc","intervention_type":"Drug"},{"arm_group_label":"Maraviroc + Boceprevir","intervention_description":"Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food","intervention_name":"Maraviroc + Boceprevir","intervention_type":"Drug"},{"arm_group_label":"Maraviroc + Telaprevir","intervention_description":"Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food","intervention_name":"Maraviroc + Telaprevir","intervention_type":"Drug"}],"interventional_subtype":"Basic Science","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":["maraviroc","boceprevir","telaprevir","drug interaction","pharmacokinetics","HIV"],"last_follow_up_date":"08/01/2012 00:00:00","links":[{"description":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001108&StudyName=Estimate%20the%20Effect%20of%20Telaprevir%20and%20Boceprevir%20on%20Maraviroc%20Pharmacokinetics%20in%20Healthy%20Subjects%20"}],"locations":[{"City":"Bruxelles","Latitude":"50.8238652","CountryDisplay":"Belgium","Longitude":"4.2986584","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"B-1070","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Open","maximum_age_raw":"55 Years","maximum_age":"55","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"10/01/2018 22:57:29","number_of_arms":"3","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"Open-Label, Randomized, Fixed-Sequence, Crossover Study to Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects","org_study_id":"A4001108","overall_contact":{"email":null,"last_name":"Pfizer CT.gov Call Center","phone":"1-800-718-1021"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"PHASE 1","primary_compl_date":"08/01/2012 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Maraviroc plasma pharmacokinetic parameters: AUC12, Cmax, and C12h on Period 1, Day 5 and Periods 2 and 3, Day 10","outcome_time_frame":"25 days","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Maraviroc plasma pharmacokinetic parameters: Tmax on Period 1, Day 5 and Periods 2 and 3, Day 10","outcome_time_frame":"25 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Boceprevir plasma pharmacokinetic parameters: AUC8, Cmax, C8h, and Tmax on Period 2, Day 10","outcome_time_frame":"10 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Telaprevir plasma pharmacokinetic parameters: AUC8, Cmax, C8h, and Tmax on Period 3, Day 10","outcome_time_frame":"10 days","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"None","lead_sponsor":"ViiV Healthcare","collaborators":["Pfizer"]},"start_date":"07/01/2012 00:00:00","study_type":"Interventional","therapeutic_area":"","citations":[],"is_section_801":false}},"pageContext":{"studyId":"A4001108"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}